Galderma expands Restylane(R) portfolio in Japan with launch of OBT(TM) hyaluronic acid injectables Restylane Defyne(TM) and Refyne(TM)

{
  "signal_id": "ea678255-25e3-4707-bd96-238110173131",
  "signal_type": "news",
  "signal_subtype": "launches",
  "detected_at": "2026-02-11T00:00:00+00:00",
  "company": {
    "name": "Galderma",
    "domain": "galderma.com"
  },
  "data": {
    "url": "https://www.galderma.com/news/galderma-expands-restylane-portfolio-japan",
    "title": "Galderma expands Restylane(R) portfolio in Japan with launch of OBT(TM) hyaluronic acid injectables Restylane Defyne(TM) and Refyne(TM)",
    "excerpt": "Galderma expands Restylane(R) portfolio in Japan with launch of OBT(TM) hyaluronic acid injectables Restylane Defyne(TM) and Refyne(TM).\n\nFebruary 11, 2026\n\n* Restylane(R) Refyne(TM) and Restylane Defyne(TM) are the first Optimal Balance Technology (OBT(TM) hyaluronic acid injectables ever approved and launched in Japan, bringing advanced flexibility and natural movement to the market[1,2]\n* This expands Galderma's Restylane portfolio in Japan to four products, enabling treatment of a wider spectrum of patient and practitioner needs[3,4]\n* These two new launches underscore Galderma's accelerating growth across the Japan & Asia Pacific (JPAC) region\n\nZug, Switzerland - February 11, 2025 - Galderma (SIX: GALD), the pure-play dermatology category leader, has announced the launch of Restylane Defyne and Restylane Refyne: the first OBT-based hyaluronic acid injectables ever authorized in Japan.[1,2] The products - designed for injection into the mid-to-deep dermis for the correction of moderate to severe facial wrinkles and folds - are now commercially available in the market.[1,2]\n\nRestylane Defyne and Refyne leverage the unique balance of softness, flexibility, and support delivered by Galderma's proprietary OBT - designed to move in harmony with facial expressions while maintaining shape and lift - and are the first and only hyaluronic acid injectables clinically proven to...",
    "product": "Restylane Defyne and Restylane Refyne",
    "summary": "Galderma Pharma S.A launched Restylane Defyne and Restylane Refyne on Feb 11th '25.",
    "category": "launches",
    "found_at": "2026-02-11T00:00:00Z",
    "location": "Japan",
    "planning": false,
    "image_url": "https://www.galderma.com//sites/default/files/Galderma_Logo.jpg",
    "confidence": 0.7301,
    "product_data": {
      "full_text": "Restylane Defyne and Restylane Refyne",
      "fuzzy_match": true
    },
    "published_at": "2026-02-11T00:00:00Z",
    "location_data": [
      {
        "country": "Japan",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2025-02-11",
    "article_sentence": "Zug, Switzerland - February 11, 2025 - Galderma (SIX: GALD), the pure-play dermatology category leader, has announced the launch of Restylane Defyne and Restylane Refyne: the first OBT-based hyaluronic acid injectables ever authorized in Japan."
  }
}

curl https://signals.autobound.ai/v1/signals/ea678255-25e3-4707-bd96-238110173131 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"galderma.com","limit":20}'